| MEDI | Monday, 27 March 2006 | ||
1:30 PM-4:30 PM Georgia World Congress Center -- Georgia Ballroom 1, Oral | |||
Current and Future Potential Drug Therapy for Parkinson's Disease | |||
| Organizer: | Jeff A. Zablocki | ||
| 1:30 PM | 172 | Progress on the etiology, modeling and treatment of Parkinson's disease Michael A. Schwarzschild | |
| 2:00 PM | 173 | Adenosine A2A antagonists: New therapeutic approach against Parkinson's disease Junichi Shimada | |
| 2:30 PM | 174 | Novel triazolopyrazine, triazolopyrimidine, and triazolotriazine derivatives as potent and selective adenosine A2a receptor antagonists Gnanasambandam Kumaravel, Thomas Engber, Chi B Vu, Hairuo Peng, James E Dowling, Gang Yao, Jeffery T Vessels, Daniel Scott, Russell C Petter | |
| 3:00 PM | 175 | Dual-mechanism MAO-B inhibitors and A2A antagonists in Parkinson's disease therapy Cornelus J. Van der Schyf, Jacobus P. Petzer, Kay P. Castagnoli, Jiang-Fan Chen, Michael A. Schwarzchild, N. Castagnoli Jr. | |
| 3:30 PM | 176 | α-Synuclein misfolding and aggregation: drug discovery target for Parkinson's disease Hiroshi Kase, Hiromi Nonaka | |
| 4:00 PM | 177 | Second generation MLK inhibitors Robert L. Hudkins | |
Symposium Grid -- Division of Medicinal Chemistry -- Session Listing
Symposium Grid -- Drug Discovery -- Session Listing
The 231st ACS National Meeting, Atlanta, GA, March 26-30, 2006